Results 131 to 140 of about 6,539 (200)

Feasibility of a 50% Dosing Interval Extension of Anti-IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study. [PDF]

J Asthma Allergy
Vergles M, Salai G, Tudorić N, Kovačević I, Kifer D, Lalić K, Gomerčić Palčić M, Vukić Dugac A.   +7 more
europepmc   +1 more source

Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a <i>post hoc</i> analysis of the ANANKE study. [PDF]

ERJ Open Res
Senna G, Brussino L, Aliani M, Altieri E, Bracciale P, Caiaffa MF, Cameli P, Canonica GW, Caruso C, Centanni S, De Michele F, Del Giacco S, Di Marco F, Malerba L, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, D'Amato M, Caminati M.   +22 more
europepmc   +1 more source

Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review. [PDF]

Front Med (Lausanne)
Alzayed A.
europepmc   +1 more source

Successful Treatment of Steroid-Dependent Severe Eosinophilic Pneumonia With Benralizumab: A Case Report. [PDF]

Respirol Case Rep
Ichikawa T, Takigawa Y, Fujiwara K, Inoue T, Matsumoto S, Shiraha K, Goda M, Matsuoka S, Watanabe H, Kudo K, Sato A, Sato K, Shibayama T.   +12 more
europepmc   +1 more source

Clinical relevance of CompEx Asthma and impact on disease trajectory: benralizumab effect. [PDF]

ERJ Open Res
Bolton C, Akuthota P, Lugogo N, Barker P, Bengtsson T, Peterson S, Siddiqui S, Da Silva CA.   +7 more
europepmc   +1 more source

Mirror, mirror on the wall: is CompEx the fairest endpoint of all? [PDF]

ERJ Open Res
Hung CT, Erickson SR, Wu CH.
europepmc   +1 more source

Unmasking EGPA with near fatal diffuse alveolar haemorrhage in severe eosinophilic asthma under treatment with benralizumab: a case report. [PDF]

BMC Pulm Med
Drick N, Kaireit TF, Ruwisch J, Schallhorn S, Bauersachs J, Schenk H, Hoeper MM, Witte T, Seeliger B.   +8 more
europepmc   +1 more source

Safety and efficacy of anti-IL-5 monoclonal antibodies as second-line therapy for chronic rhinosinusitis with nasal polyps: a meta-analysis. [PDF]

Front Immunol
Liao H, Qiu C, Luo Y, Chen J, Qin C, Quan J, Liang W, Qin J, Chen R.   +8 more
europepmc   +1 more source

Real-world outcomes after anti-IL-5/anti-IL-5Rα treatment for hypereosinophilic syndrome: Systematic literature review. [PDF]

J Allergy Clin Immunol Glob
Jain P, Rowell J, Edmonds C, Stokes M, Ding N, Chen SY.   +5 more
europepmc   +1 more source